Comprehensive patient assessment and accurate risk stratification are cornerstones of effective inpatient management of SARS-CoV-2. However, the absence of a clear consensus on how to categorize patients by risk—and the limited availability of validated, reliable scoring systems—continues to challenge clinical …
The ongoing evolution of the SARS-CoV-2 virus has led to the emergence of multiple regional variants with varying genetic profiles and clinical implications. These differences significantly impact the efficacy of inpatient COVID-19 treatment strategies, including antiviral use, monoclonal antibody therapy, …
Pre-exposure prophylaxis (PrEP) is an established and highly effective method of preventing sexually transmitted human immunodeficiency virus (HIV) infections and has been instrumental in declining incidence rates. Adherence and access to HIV prevention still pose challenges due to stigma and …
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus resulting from the accumulation of eosinophils in the esophageal lining and tissue damage. Patients face the daily struggles of difficulty swallowing, upper gastrointestinal morbidity, and diminished quality of …
Chronic, subacute, and acute pain remain among the most common and complex challenges encountered in clinical practice. Inadequate pain management contributes to diminished quality of life, impaired function, and increased healthcare utilization. At the same time, the ongoing opioid crisis …
The Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit is designed to give Medicaid-insured children the strongest possible start by offering age-appropriate screenings, comprehensive preventive care, and timely treatment. In practice, however, many families still encounter frustrating gaps between …
Complicated urinary tract infections (cUTIs) represent an important and growing challenge in clinical practice, affecting individual patients’ health and quality of life while exerting a substantial burden on the healthcare system. Despite being common, these infections are underrecognized. The July …
Accurately distinguishing HER2-low and ultralow expression in metastatic breast cancer (mBC) is critical, yet it presents unique challenges for pathologists. Traditional binary HER2 classifications no longer meet clinical needs, as the availability of antibody-drug conjugates (ADCs) now depend on more …
The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes …